Comparative Pharmacology
Head-to-head clinical analysis: CAPRELSA versus VITRAKVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPRELSA versus VITRAKVI.
CAPRELSA vs VITRAKVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and oncogenesis, including VEGFR2, EGFR, and RET.
Larotrectinib is a selective inhibitor of the tropomyosin receptor kinases (TRK) A, B, and C. It binds to the ATP-binding site of TRK kinases, preventing their activation and downstream signaling pathways, thereby inhibiting proliferation and inducing apoptosis in tumors with NTRK gene fusions.
300 mg orally once daily, with or without food.
100 mg orally twice daily
None Documented
None Documented
Terminal half-life approximately 90 hours (range 30–150 hours), supporting once-daily dosing; steady-state achieved by day 15.
Terminal elimination half-life is approximately 16.2 hours (range 12-20 h) in patients; supports twice-daily dosing.
Primarily fecal (approximately 75% of administered dose, mainly as unchanged drug and metabolites); renal excretion accounts for about 25% (less than 1% unchanged).
Primarily hepatic metabolism, with 39% recovered in feces (36% as unchanged drug) and 18% in urine (0.5% unchanged).
Category C
Category C
Kinase Inhibitor
Kinase Inhibitor